Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing ...

A2 Bio shares clinical study progress and the increased diversity of participants in the BASECAMP-1 prescreening study during ...

Scientists have demonstrated a creative new way to kill cancer cells effectively, with few side effects. Gluing two ...

AgenT-797 combined with bispecific engagers targeting antigens such as MUC16, HER2, Claudin 18.2, and DLL3, promote increased ...

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported ...

Researchers reveal how an ingredient in traditional Chinese medicine may hold the secret to creating a new treatment for ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta ...

Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor ...

Robles BioCeutics LLC, a regenerative dermatology company, is pleased to announce a new collaboration with BioCentrium aimed at advancing research into the molecular mechanisms behind ...

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...